Growth & profitability
- Revenue has declined 65.1% per year over the past 5 years.
Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
VIR Financials Vir Biotechnology, Inc.
9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $69M | -$438M | 100.0% | -699.2% | -$397M | — | $232M |
| 2024 | $74M | -$522M | 98.9% | -791.3% | -$454M | — | $223M |
| 2023 | $86M | -$615M | 96.8% | -794.0% | -$800M | — | $242M |
| 2022 | $1.6B | $516M | 90.9% | 51.6% | $1.6B | — | $849M |
| 2021 | — | $529M | — | — | -$69M | — | $348M |
| 2020 | — | -$299M | — | — | -$197M | — | $437M |
| 2019 | — | -$175M | — | — | -$139M | — | $109M |
| 2018 | — | -$116M | — | — | -$102M | — | $48M |
| 2017 | — | -$70M | — | — | -$69M | — | $188M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | -$29000 | -$126M | 0.0% | 456172.4% | -$133M | — | $274M |
| Dec '25 | $64M | -$43M | 0.0% | -74.8% | -$26M | — | $232M |
| Sep '25 | $240000 | -$163M | 0.0% | -72267.9% | -$168M | — | $170M |
| Jun '25 | $1M | -$111M | 99.1% | -9754.3% | -$123M | — | $211M |
| Mar '25 | $3M | -$121M | 100.0% | -4602.5% | -$80M | — | $274M |
| Dec '24 | $12M | -$105M | 94.5% | -946.7% | -$90M | — | $223M |
| Sep '24 | $2M | -$214M | 97.9% | -9718.7% | -$174M | — | $168M |
| Jun '24 | $3M | -$138M | 98.3% | -5158.7% | -$79M | — | $297M |
| Mar '24 | $56M | -$65M | 99.9% | -142.0% | -$111M | — | $161M |
| Dec '23 | $17M | -$116M | 95.2% | -828.1% | -$109M | — | $242M |
| Sep '23 | $3M | -$163M | 98.6% | -7075.9% | -$160M | — | $452M |
| Jun '23 | $4M | -$195M | 99.4% | -5667.3% | -$399M | — | $667M |
| Mar '23 | $63M | -$141M | 97.0% | -227.7% | -$133M | — | $825M |
| Dec '22 | $49M | -$102M | 87.9% | -304.6% | $23M | — | $849M |
| Sep '22 | $375M | $175M | 94.1% | 52.1% | $99M | — | $964M |
| Jun '22 | -$41M | -$76M | 168.7% | 554.3% | $940M | — | $1.5B |
| Mar '22 | $1.2B | $519M | 92.7% | 82.3% | $534M | — | $812M |
| Dec '21 | $813M | $525M | 93.0% | 70.3% | -$5M | — | $348M |
| Sep '21 | $104M | $110M | 92.4% | -51.5% | -$112M | — | $715M |
| Jun '21 | $177M | $62M | 99.4% | 34.5% | $138M | — | $742M |
Valuation over time
How the market has priced VIR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 7.6× (Mar '23) to 3.3× (Dec '23).
- The price-to-sales ratio has risen from 2.4× (Mar '23) to 24.3× (Jun '26).
P/E
P/S
Frequently asked questions
Is VIR growing its revenue and profit?
Over the past 5 years, Vir Biotechnology, Inc.'s revenue has declined 65.1% per year. These are computed facts, not advice.
How much debt does VIR have?
As of FY2025, Vir Biotechnology, Inc. reported — of total debt against $232M of cash.
What is VIR's profit margin?
In FY2025, gross margin was 100.0%, operating margin -699.2%, and net margin -638.9%.
What is VIR's P/E ratio?
As of Jun '26, Vir Biotechnology, Inc. traded at a price-to-earnings ratio of about 3.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.